Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New concepts in treatment protocols for severe systemic vasculitis

W L Gross1

  • 1Dep. Rheumatologie des Universität Lübeck und Rheumaklinik Bad Bramstedt GmbH, Germany.

Current Opinion in Rheumatology
|January 23, 1999
PubMed
Summary

Glucocorticosteroids are standard for giant cell arteritis but cause complications. Alternative therapies like azathioprine, methotrexate, and depot GCs offer potential benefits for managing this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

Der Internist·2016
Same author

[Future integrated health care in internal medicine: primary hypertension and polyangiitis with granulomatosis as modell diseases].

Deutsche medizinische Wochenschrift (1946)·2015
Same author

[Genetic architecture of chronic inflammatory diseases].

Der Internist·2014
Same author

[Genetic risk factors for vasculitis].

Der Internist·2013
Same author

Genetics of toll like receptor 9 in ANCA associated vasculitides.

Annals of the rheumatic diseases·2013
Same author

[Hypereosinophilic syndrome].

Der Internist·2013

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Giant cell arteritis (GCA) treatment primarily relies on glucocorticosteroids (GCs).
  • Long-term GC therapy often leads to significant treatment-related complications.
  • Identifying effective GC-sparing strategies is crucial for managing GCA patients.

Purpose of the Study:

  • To review current and emerging therapeutic options for giant cell arteritis.
  • To evaluate the efficacy and safety of various immunosuppressive and immunomodulatory agents.
  • To highlight alternatives to long-term oral glucocorticosteroid therapy.

Main Methods:

  • Literature review of studies on GCA and related vasculitides.
  • Analysis of clinical trial data on immunosuppressants and biologics.
  • Comparison of treatment outcomes, including efficacy and adverse events.

Main Results:

  • Azathioprine and methotrexate show promise as GC-sparing agents.
  • Depot GCs administered intramuscularly reduced cumulative dosage and bone complications compared to oral GCs.
  • Other agents like mycophenolate mofetil, leflunomide, and interferon-alpha demonstrate potential in specific vasculitides or treatment-resistant cases.

Conclusions:

  • While GCs remain first-line for GCA, alternative and steroid-sparing strategies are essential.
  • Novel therapeutic approaches are emerging for various vasculitides, offering new hope for complex cases.
  • Further research is needed to establish optimal long-term management protocols for GCA and related conditions.

Related Experiment Videos